Adam Feuerstein
Articles written for the GLP list the source as Genetic Literacy Project. All other articles were written for the sources noted with excerpts provided by the GLP.
Gilead’s remdesivir offers little benefit for coronavirus patients in early trial
The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from ...
CRISPR therapy demonstrates ‘real curative potential’ for sickle cell disease, beta thalassemia
The first two patients to receive a CRISPR-based treatment for the inherited blood disorders sickle cell disease and beta thalassemia ...
Patient’s ‘serious’ kidney injury halts gene therapy trial for Duchenne muscular dystrophy
The Food and Drug Administration has halted a clinical trial involving a Duchenne muscular dystrophy gene therapy from Solid Biosciences ...
Animal safety concerns prompt FDA to halt study testing Zolgensma gene therapy for spinal muscular atrophy
The Food and Drug Administration has halted a clinical trial of Novartis’ Zolgensma gene therapy due to a safety concern ...
Podcast: Talking CRISPR with controversial biohacker Josiah Zayner
Is biohacking a crime? Who came up with the latest CRISPR trick? And did Rage Against the Machine sell out? ...
Biohacker Josiah Zayner meets with California regulators investigating him: ‘It was surreal’
A few weeks ago, the prominent biohacker Josiah Zayner took to Instagram to break some news: He had received a ...
Gene therapy for beta-thalassemia blood disorder one step closer to European approval
The first gene therapy to treat a rare blood disorder is one step closer to approval [March 29] following a ...
‘Game-changing’ drug first ever postpartum depression medication approved by FDA
The Food and Drug Administration on [March 19] approved brexanolone, the first drug specifically targeted to treat postpartum depression — ...
Promising Alzheimer’s drug trial halted
Alzheimer’s disease has beaten back another effort to tame it. Biogen and its Japanese pharma partner Eisai said [March 21] ...
